High Impact Relationships Accelerate Results
In medicine, we know that successful treatment regimens require understanding how to deploy the right drug or drug combination at the right time. That’s why Exelixis is committed to forming strategic collaborations that maximize the broad clinical potential of our FDA-approved cancer treatments, as well as our experimental molecules alone and in combination with other therapeutic agents. We have a deep pipeline strategy for our flagship product, cabozantinib, and are focused on optimizing the molecule through broad clinical development.
Our model for value creation is built upon a disciplined use of resources and a vast oncology clinical development and commercialization network. Our strategy is enhanced by our history of prolific drug discovery, aptitude for recognizing the missed potential of validated targets, and ability to focus on oncology assets that are asymmetrically valued or misunderstood. With a focused, nimble team, we fully commit to our programs and partnerships.
Exelixis’ history of productive drug discovery includes partnering multiple compounds and programs with leading pharmaceutical and biopharmaceutical companies Bristol-Myers Squibb Company, Daiichi-Sankyo Company Limited, Genentech, a member of the Roche Group, Ipsen, Merck (known as MSD outside of the United States and Canada), Sanofi and Takeda Pharmaceutical Company Limited. These U.S. and global collaborations cover a variety of compounds and programs with potential for use in the treatment of cancer, inflammation and cardiovascular and metabolic diseases.